<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117104</url>
  </required_header>
  <id_info>
    <org_study_id>20030133</org_study_id>
    <nct_id>NCT00117104</nct_id>
  </id_info>
  <brief_title>Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis</brief_title>
  <official_title>A Multicenter Study Evaluating Once Weekly Intravenous Administration of Aranesp® in Subjects With End Stage Renal Disease on Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once
      weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either
      recombinant human erythropoietin (rHuEPO) naïve or subjects converted from rHuEPO therapy
      administered IV thrice weekly (TIW).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target hemoglobin (Hgb)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of hemoglobin (Hgb) values by week</measure>
  </secondary_outcome>
  <condition>End Stage Renal Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aranesp®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects with end stage renal disease (ESRD) on hemodialysis
        Exclusion Criteria: - Known hypersensitivity to Aranesp® (darbepoetin alfa) or any of its
        excipients - Participating in an investigational drug or device trial - Patient will not be
        available for follow-up assessment - Patient has any disorder that compromises the ability
        of the patient to give written informed consent and/or to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2005</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>End Stage Renal Disease (ESRD)</keyword>
  <keyword>Kidney Disease, Dialysis</keyword>
  <keyword>Aranesp®, rHuEPO</keyword>
  <keyword>Anemia, Hemoglobin</keyword>
  <keyword>Dosing, Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

